CoChat
Sign Up
Cited by 98

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

New strategies for targeting matrix metalloproteinases.

Fields, Gregg B.·2015·Matrix Biology
DOI 10.1016/j.matbio.2015.01.002PMC PMC4466128
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.matbio.2015.01.002

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Hu, 2007, Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases, Nat Rev Drug Discov, 6, 480, 10.1038/nrd2308 · DOI
  2. Rivera, 2010, Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?, J Neurosci, 30, 15337, 10.1523/JNEUROSCI.3467-10.2010 · DOI · Paper page
  3. Troeberg, 2012, Proteases involved in cartilage matrix degradation in osteoarthritis, Biochim Biophys Acta, 1824, 133, 10.1016/j.bbapap.2011.06.020 · DOI
  4. Sbardella, 2012, Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes, Mol Aspects Med, 33, 119, 10.1016/j.mam.2011.10.015 · DOI
  5. Newby, 2012, Matrix metalloproteinase inhibition therapy for vascular diseases, Vascul Pharmacol, 56, 232, 10.1016/j.vph.2012.01.007 · DOI
  6. Lindsey, 2012, Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction, Cardiovasc Ther, 30, 31, 10.1111/j.1755-5922.2010.00207.x · DOI
  7. Whittaker, 1999, Design and therapeutic application of matrix metalloproteinase inhibitors, Chem Rev, 99, 2735, 10.1021/cr9804543 · DOI
  8. Jacobsen, 2010, To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition, Biochim Biophys Acta, 1803, 72, 10.1016/j.bbamcr.2009.08.006 · DOI
  9. Saghatelian, 2004, Activity-based probes for the proteomic profiling of metalloproteases, Proc Natl Acad Sci U S A, 101, 10000, 10.1073/pnas.0402784101 · DOI
  10. Peterson, 2006, The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors, Cardiovasc Res, 69, 677, 10.1016/j.cardiores.2005.11.032 · DOI
  11. Becker, 2010, Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease, J Med Chem, 53, 6653, 10.1021/jm100669j · DOI
  12. Devy, 2011, New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies, Biochem Res Int, 2011, 191670, 10.1155/2011/191670 · DOI
  13. Baragi, 2009, A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models, Arthritis Rheum, 60, 2008, 10.1002/art.24629 · DOI
  14. Lauer-Fields, 2007, Triple-helical transition-state analogs: a new class of selective matrix metalloproteinase inhibitors, J Am Chem Soc, 129, 10408, 10.1021/ja0715849 · DOI
  15. Morrison, 2009, Matrix metalloproteinase proteomics: substrates, targets, and therapy, Curr Opin Cell Biol, 21, 645, 10.1016/j.ceb.2009.06.006 · DOI
  16. Sela-Passwell, 2011, New opportunities in drug design of metalloproteinase inhibitors: combination between structure–function experimental approaches and systems biology, Expert Opin Drug Discovery, 6, 527, 10.1517/17460441.2011.560936 · DOI
  17. Sela-Passwell, 2010, Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?, Biochim Biophys Acta, 1803, 29, 10.1016/j.bbamcr.2009.04.010 · DOI
  18. Udi, 2013, Unraveling hidden regulatory sites in structurally homologous metalloproteases, J Mol Biol, 425, 2330, 10.1016/j.jmb.2013.04.009 · DOI
  19. Ndinguri, 2012, Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities, Molecules, 17, 14230, 10.3390/molecules171214230 · DOI
  20. Engel, 2005, Structural basis for the highly selective inhibition of MMP-13, Chem Biol, 12, 181, 10.1016/j.chembiol.2004.11.014 · DOI
  21. Gooljarsingh, 2008, Characterization of an exosite binding inhibitor of matrix metalloprotease 13, Protein Sci, 17, 66, 10.1110/ps.073130208 · DOI
  22. Johnson, 2007, Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects, J Biol Chem, 282, 27781, 10.1074/jbc.M703286200 · DOI
  23. Li, 2008, Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis, J Med Chem, 51, 835, 10.1021/jm701274v · DOI
  24. Settle, 2010, Arthritis Rheum, 62, 3006, 10.1002/art.27596 · DOI
  25. Jüngel, 2010, Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis, Ann Rheum Dis, 69, 898, 10.1136/ard.2008.106021 · DOI
  26. Piecha, 2010, Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants, Inflamm Res, 59, 379, 10.1007/s00011-009-0112-9 · DOI
  27. Gege, 2012, Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis, J Med Chem, 55, 709, 10.1021/jm201152u · DOI
  28. Chen, 2000, Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design, J Am Chem Soc, 122, 9648, 10.1021/ja001547g · DOI
  29. Blagg, 2005, Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14, Bioorg Med Chem Lett, 15, 1807, 10.1016/j.bmcl.2005.02.038 · DOI
  30. Reiter, 2006, Potent, selective pyrimidinetrione-based inhibitors of MMP-13, Bioorg Med Chem Lett, 16, 5822, 10.1016/j.bmcl.2006.08.066 · DOI
  31. Shah, 2012, An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer, PLoS One, 7, e29615, 10.1371/journal.pone.0029615 · DOI
  32. Heim-Riether, 2009, Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors, Bioorg Med Chem Lett, 19, 5321, 10.1016/j.bmcl.2009.07.151 · DOI
  33. Gao, 2010, SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability, Bioorg Med Chem Lett, 20, 5039, 10.1016/j.bmcl.2010.07.036 · DOI
  34. Spicer, 2014, Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro, J Med Chem, 57, 9598, 10.1021/jm501284e · DOI
  35. Lauer-Fields, 2009, High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate, Bioorg Med Chem, 17, 990, 10.1016/j.bmc.2008.03.004 · DOI
  36. Roth, 2011, Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds, Bioorg Med Chem Lett, 21, 7180, 10.1016/j.bmcl.2011.09.077 · DOI
  37. Nara, 2014, Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site, Bioorg Med Chem, 22, 5487, 10.1016/j.bmc.2014.07.025 · DOI
  38. Fischer, 2013, Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors, ChemMedChem, 8, 1457, 10.1002/cmdc.201300278 · DOI
  39. Woskowicz, 2013, MT-LOOP-dependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion, J Biol Chem, 288, 35126, 10.1074/jbc.M113.496067 · DOI
  40. Ingvarsen, 2013, Targeting a single function of the multifunctional matrix metalloproteinase MT1-MMP: impact on lymphangiogenesis, J Biol Chem, 288, 10195, 10.1074/jbc.M112.447169 · DOI
  41. Shiryaev, 2013, A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP, Oncog, 2, e80, 10.1038/oncsis.2013.44 · DOI · Paper page
  42. Zhu, 2011, High-affinity peptide against MT1-MMP for in vivo tumor imaging, J Control Release, 150, 248, 10.1016/j.jconrel.2011.01.032 · DOI
  43. Remacle, 2012, Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth, Cancer Res, 72, 2339, 10.1158/0008-5472.CAN-11-4149 · DOI
  44. Xu, 2007, Inhibition of MMP-2 gelatinolysis by targeting exodomain–substrate interactions, Biochem J, 406, 147, 10.1042/BJ20070591 · DOI
  45. Lauer-Fields, 2008, Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition, J Biol Chem, 283, 20087, 10.1074/jbc.M801438200 · DOI
  46. Gall, 2001, Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state, J Mol Biol, 307, 577, 10.1006/jmbi.2001.4493 · DOI
  47. Babine, 1997, Molecular recognition of protein–ligand complexes: applications to drug design, Chem Rev, 97, 1359, 10.1021/cr960370z · DOI
  48. Lauer-Fields, 2009, Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity, J Biol Chem, 284, 24017, 10.1074/jbc.M109.016873 · DOI
  49. Bertini, 2012, Structural basis for matrix metalloproteinase 1 catalyzed collagenolysis, J Am Chem Soc, 134, 2100, 10.1021/ja208338j · DOI
  50. Manka, 2012, Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1, Proc Natl Acad Sci U S A, 109, 12461, 10.1073/pnas.1204991109 · DOI
  51. Lauer-Fields, 2002, Matrix metalloproteinases and collagen catabolism, Biopolymers (Pept. Sci), 66, 19, 10.1002/bip.10201 · DOI
  52. Fan, 2008, Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold, FASEB J, 22, 3795, 10.1096/fj.08-111484 · DOI
  53. Ndinguri, 2012, Application of collagen-model triple-helical peptide-amphiphiles for CD44 targeted drug delivery systems, J Drug Deliv, 2012, 592602, 10.1155/2012/592602 · DOI
  54. Yasui, 2013, Potential of collagen-like triple helical peptides as drug carriers: their in vivo distribution, metabolism, and excretion profiles in rodents, Biopolymers (Pept Sci), 100, 705, 10.1002/bip.22234 · DOI
  55. Bhowmick, 2011, Efficient synthesis of fmoc-protected phosphinic pseudodipeptides: building blocks for the synthesis of matrix metalloproteinase inhibitors (MMPIs), Biopolymers (Pept Sci), 96, 1, 10.1002/bip.21425 · DOI
  56. Bhowmick, 2012, Synthesis of Fmoc-Gly-Ile phosphinic pseudodipeptide: residue specific conditions for construction of matrix metalloproteinase inhibitor building blocks, Int J Peptide Res & Ther, 18, 335, 10.1007/s10989-012-9307-y · DOI
  57. de Castro Brás, 2014, Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the post-myocardial infarction left ventricle, Antioxid Redox Signal, 21, 1974, 10.1089/ars.2013.5411 · DOI
  58. Uttamchandani, 2007, Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library, J Am Chem Soc, 129, 7848, 10.1021/ja070870h · DOI
  59. Minond, 2007, Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences, Biochemistry, 46, 3724, 10.1021/bi062199j · DOI
  60. Paemen, 1995, Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity, Eur J Biochem, 234, 759, 10.1111/j.1432-1033.1995.759_a.x · DOI
  61. Martens, 2007, A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains, Biochim Biophys Acta, 1770, 178, 10.1016/j.bbagen.2006.10.012 · DOI
  62. Hu, 2004, Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody, Biochem Pharmacol, 67, 1001, 10.1016/j.bcp.2003.10.030 · DOI
  63. Pruijt, 1999, Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9), Proc Natl Acad Sci U S A, 96, 10863, 10.1073/pnas.96.19.10863 · DOI
  64. Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res, 69, 1517, 10.1158/0008-5472.CAN-08-3255 · DOI
  65. Zucker, 2009, Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?, Cancer Biol Ther, 8, 1, 10.4161/cbt.8.24.10353 · DOI
  66. Sela-Passwell, 2011, Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential, Nat Med, 18, 143, 10.1038/nm.2582 · DOI
  67. Fields, 2014, Biophysical studies of matrix metalloproteinase (MMP)/triple-helix complexes, vol. 97, 37, 10.1016/bs.apcsb.2014.09.001 · DOI

Cited by

Sorted by citations

Metadata

Authors
Fields, G. B.
Venue
Matrix Biology
Publisher
Elsevier BV
Published
2015-05
Volume
44-46
Pages
239-246
ISSN
0945-053X
DOI
10.1016/j.matbio.2015.01.002
PMC
PMC4466128
Cited by
98
References
2
Language
en
Licence
Funders
  • NIH (CA98799, AR063795, GM106469)
  • NHLBI (268201000036C))
  • Multiple Sclerosis National Research Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review